| Literature DB >> 25611390 |
J Xu1, S E Eriksson1, M Cebula1, T Sandalova2, E Hedström3, I Pader1, Q Cheng1, C R Myers4, W E Antholine5, P Nagy6, U Hellman7, G Selivanova3, Y Lindqvist2, E S J Arnér1.
Abstract
The selenoprotein thioredoxin reductase 1 (TrxR1) has several key roles in cellular redox systems and reductive pathways. Here we discovered that an evolutionarily conserved and surface-exposed tryptophan residue of the enzyme (Trp114) is excessively reactive to oxidation and exerts regulatory functions. The results indicate that it serves as an electron relay communicating with the FAD moiety of the enzyme, and, when oxidized, it facilitates oligomerization of TrxR1 into tetramers and higher multimers of dimers. A covalent link can also be formed between two oxidized Trp114 residues of two subunits from two separate TrxR1 dimers, as found both in cell extracts and in a crystal structure of tetrameric TrxR1. Formation of covalently linked TrxR1 subunits became exaggerated in cells on treatment with the pro-oxidant p53-reactivating anticancer compound RITA, in direct correlation with triggering of a cell death that could be prevented by antioxidant treatment. These results collectively suggest that Trp114 of TrxR1 serves a function reminiscent of an irreversible sensor for excessive oxidation, thereby presenting a previously unrecognized level of regulation of TrxR1 function in relation to cellular redox state and cell death induction.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25611390 PMCID: PMC4669772 DOI: 10.1038/cddis.2014.574
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1RITA treatment promotes the formation of covalently linked TrxR1 oligomers in cancer cells that can be prevented by NDGA and correlate with cell death. (a) RITA (1 μM) treatment of HCT116 cells for 8 h triggers the formation of an ≈110 kDa TrxR1-positive band seen in western blots.[13] Here TrxR1-derived protein species were enriched from HCT116 cells (controls or treated with RITA, as indicated) by immunoprecipitation, visualized by Coomassie staining and further analyzed by tryptic digests and mass spectrometry (Supplementary Table S1). (b, c) Pre-treatment of HCT116 cells using 50 μM NDGA for 1 h blocked RITA-induced formation of TrxR1 dimeric bands as seen on western blots, also further verified using knockdown of TrxR1 with siRNA (Siseq1 and Siseq2). Below the western blots, the results of densitometric quantifications of dimer over monomer ratios are shown. See text for details. DEDA, 7,7-dimethyl-(5Z,8Z)-eicosadienoic acid 25 or 50 μM (phospholipase A2 inhibitor, sPLA2 and cPLA2); Indo, indomethacin 20 μM (Cox 1, 2 inhibitor); MAFP, methyl arachidonyl fluorophosphonate 10 μM (phospholipase A2 inhibitor, cPLA2 and iPLA2); NDGA, nordihydroguareric acid 50 μM; PM, pyridoxamine dihydrochloride 2 mM; SA, salicylamine 2 mM (to scavenge lipid-derived ketoaldehydes). (d) NDGA treatment prevents RITA-induced cell death in HCT116 cells. (e) TrxR1 oligomers in cell lysates, as indicated, were fractionated using gel filtration (left), whereupon all fractions were analyzed for TrxR activity (middle) and band sizes as detected using western blot of reducing SDS-PAGE analyses (right). The expected migration over the gel filtration column of different TrxR1 oligomers in solution is also indicated as the number of TrxR1 subunits that would be required to yield the corresponding elution (top, right panel)
Figure 2Surface-exposed Trp114 links TrxR1 dimers into tetramers, communicates with the FAD and is required for full enzyme activity. (a) Crystal structure of the TrxR1 tetramer, showing two dimers (yellow/purple and green/blue) linked together by the interaction of two modified Trp114 residues (middle, surface between the yellow and blue subunits of the two separate dimers; here with their modified side chains indicated by the composite omit electron density map). (b) Close-up of the final 2Fo-Fc map at 1σ of the region where two modified Trp114 side chains link the two TrxR1 dimers in the tetramer structure (one dimer here colored green and the other yellow). The electron density spanning the linkage could not be modeled with any known modifications of Trp residues and the Trp114 side chains are therefore only shown as electron density. Neighboring residues from each dimer are indicated with their three letter codes. (c) NBS irreversibly inhibits TrxR1. For this experiment, wild-type dimeric TrxR1 was incubated in the dark with NBS at the indicated concentrations for 60 min, desalted and subsequently enzyme activities were measured with either DTNB or Trx-dependent insulin reduction. (d) Free Trp in solution protects TrxR1 from inhibition by incubation for 120 min with 50 μM NBS. (e) 3D fluorescence excitation/emission spectra reveal long-range communication between Trp114 and FAD. Typical enzyme-bound flavin fluorescence[53] at Emmax≈520 nm has three excitation peaks of Exmax≈280 nm, ≈370 nm and ≈470 nm as seen in wild-type TrxR1, whereas one of these fluorescence peaks, Exmax≈470 nm/Emmax≈520 nm (block arrows), was virtually absent in the Trp114 variants, where instead a new peak at Exmax≈370 nm/Emmax≈440 nm was seen (thin arrows). (f) Representative EPR analysis of wild-type TrxR and the W114R variant. For these spectra, TrxR (300 μM dimer) was incubated with 900 μM NADPH for 80 s. In the absence of NADPH, the oxidized enzymes did not show this signal, nor did NADPH without enzyme. The bar graph at right shows the relative EPR signal intensities of wild-type TrxR (wtTrxR) and the W114R variant incubated with an excess of NADPH to generate the reduced (EH4) state of the enzyme, or with a limiting amount of NADPH to generate a partially reduced (EH2) state. *P<0.05 or **P<0.01 for W114R versus wtTrxR. EPR instrument settings are described in the Materials and methods section. (g) Immunoblot detection of different TrxR1 species with antibodies against either TrxR1 (top) or the FLAG-tag (bottom) as resolved on reducing SDS-PAGE analyses with lysates from HCT116 cells transfected for expression of FLAG-tagged wild-type TrxR1 (WT), the W114R mutant or non-transfected controls, treated with either RITA, RITA and NDGA or using non-treated control cells (as indicated)
Steady-state kinetic parameters of TrxR1 variants
| 1130±21 | 596±8 | 106±2 | < 3 | 102±1 | ||
| 7.9±0.3 | 6.5±0.2 | 36.9±1.2 | NA | 37.2±0.9 | ||
| 144 | 92 | 3 | NA | 3 | ||
| 2548±66 | 1312±41 | 1192±23 | 327±20 | 1003±27 | ||
| 212.8±15.9 | 207.1±18.9 | 101.5±5.9 | 309.7±47.6 | 263.7±18.9 | ||
| 12 | 6 | 12 | 1 | 4 | ||
| 797±32 | 1192±72 | 594±28 | 876±54 | 1361±105 | ||
| 7.6±1.0 | 6.8±1.3 | 6.3±1.0 | 8.4±1.6 | 8.9±2.1 | ||
| 105 | 176 | 95 | 104 | 153 | ||
| 479±20 | 270.5±13 | 216 ±15 | 104±6 | 202±8 | ||
| | 2.6±0.4 | 1.9±0.4 | 1.1±0.4 | 1.4±0.3 | 1.6±0.3 | |
| 183 | 142 | 198 | 77 | 124 | ||
| 1718±30 | 959±21 | 844±37 | 309±9 | 785±21 | ||
| 3.8±0.2 | 3.7±0.3 | 4.7±0.7 | 2.4±0.3 | 4.0±0.4 | ||
| 458 | 260 | 179 | 130 | 199 | ||
| 597±19 | 339±12 | 320±12 | 137±6 | 228±7 | ||
| 1.3±0.1 | 1.4±0.1 | 1.3±0.1 | 0.8±0.1 | 1.1±0.1 | ||
| 467 | 241 | 239 | 165 | 217 | ||
NA, not applicable
Human wild-type Trx1 was used in the insulin-coupled Trx reduction assay
kcat per dimeric enzyme and Km were calculated following the formation of TNB− at 412 nm at 25 °C
kcat per dimeric enzyme and Km were calculated following NADPH oxidation at 340 nm at 25 °C